Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

CJC-1295 with DAC: what the published research shows

CJC-1295 with DAC is a GHRH analogue studied for its extended half-life via Drug Affinity Complex. This page summarises what published research reports on its pharmacology, models and evidence limits.

peptides-pro Editorial

CJC-1295 with DAC (Drug Affinity Complex) is a growth hormone-releasing hormone (GHRH) analogue, also referred to in the literature as CJC-1295 DAC or simply CJC-1295. It belongs to the class of GHRH analogues that includes sermorelin, tesamorelin and CJC-1295 without DAC, and it is grouped alongside growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin in reviews of agents intended to modulate the GH-IGF-1 axis [1]. The published evidence block used for this page does not supply a sequence, molecular formula or molecular weight for this compound, so none is stated here.

The work on this compound centres on the GHRH receptor and the downstream growth hormone-insulin-like growth factor-1 (GH-IGF-1) signalling axis [1].

Research Studies

CJC-1295 with DAC and the GH-IGF-1 axis in review literature

Reviews of performance-enhancing peptides that modulate the GH-IGF-1 axis list CJC-1295 with DAC among the GHRH analogues most commonly encountered both in clinical practice and in online self-administration protocols [1]. The same review groups it with CJC-1295 without DAC, sermorelin and tesamorelin as GHRH analogues, and separates that class from the growth hormone secretagogues, which act through a different receptor route [1]. This is a classification and mapping finding rather than an efficacy finding; the review describes where the compound sits in the pharmacological landscape, not what it achieves in a given model.

CJC-1295 with DAC and purity in gray-market testing datasets

An evaluation of research-grade peptides marketed directly to consumers analysed a large, publicly available independent testing dataset covering 6,441 samples, with the stated objective of assessing purity, measured abundance and endotoxin burden, and of comparing cost against compounded and FDA-approved alternatives [2]. That study frames the context in which these preparations circulate: a rapidly expanding drug class with a parallel and largely unregulated gray market selling preparations directly to consumers for self-administration, including for purported musculoskeletal recovery, hypertrophy, fat loss and athletic performance [2]. The finding is about the market and the analytical variability of products in it, not about the pharmacology of the molecule itself.

CJC-1295 with DAC and peptide therapeutics in gerontology

A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus and regulatory databases including the FDA and WADA [3]. Peptide therapeutics in that review are positioned as targeting hallmarks of aging such as metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [3]. CJC-1295 with DAC appears within the broader class of agents considered in this literature; the review does not report a dedicated aging outcome for this specific compound in the evidence supplied here.

CJC-1295 with DAC and musculoskeletal or performance claims

Reviews of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance describe peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and note that use in sports medicine is expanding on the back of patient demand for accelerated injury recovery and performance enhancement [4][5]. Those reviews set approved peptide drugs, which have undergone a rigorous evaluation of safety and efficacy, against a parallel gray market of unapproved compounds operating largely outside regulatory oversight [4][5]. CJC-1295 with DAC falls on the unapproved side of that divide in this framing. No controlled musculoskeletal or performance endpoint for this compound is reported in the evidence block.

CJC-1295 with DAC in a Phase 2 HIV-associated visceral obesity study

The most specific human study record in the evidence block is a multicentre, randomised, placebo-controlled, double-blind Phase 2 trial of CJC 1295 in patients with HIV-associated visceral obesity [6]. Participants were treated for a total of 12 weeks with a 6-week follow-up after treatment ended, and were randomly assigned to low-dose CJC 1295, high-dose CJC 1295 or placebo [6]. The stated objective was to assess and compare efficacy, pharmacokinetics, safety and tolerability in that population [6]. This is a registered study record describing design and objectives; the evidence block does not include reported results, so no outcome is stated here.

CJC-1295 with DAC and the wider injectable peptide literature

Structured narrative reviews of injectable peptides in sports medicine report that these agents are increasingly promoted for musculoskeletal recovery, tissue repair and performance enhancement, while clinical adoption has outpaced high-quality evidence and regulatory consensus [8]. Related reviews of peptide supplements in sports medicine note rapid market growth driven by marketing claims of enhanced performance and accelerated recovery, with these products often perceived as low risk despite the absence of efficacy or safety data [7]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides marketed as more selective and ostensibly safer alternatives [10]. These are class-level observations about the evidence base and its gaps; they are not compound-specific findings for CJC-1295 with DAC.

CJC-1295 with DAC and evidence-tier comparison

The table below summarises how the evidence block characterises the compound across the dimensions it covers. It compares what is documented rather than what is claimed.

DimensionWhat the evidence block reportsSource
ClassGHRH analogue, listed with sermorelin, tesamorelin and CJC-1295 without DAC[1]
PathwayGH-IGF-1 axis[1]
Human trial recordPhase 2, randomised, placebo-controlled, double-blind, 12 weeks treatment plus 6 weeks follow-up, in HIV-associated visceral obesity[6]
Reported outcomes in evidence blockNone supplied[6]
Regulatory status in reviewsGrouped with unapproved peptides marketed direct to patients[4][5]
Product quality contextGray-market research peptides show variability in purity and measured abundance across a 6,441-sample dataset[2]

CJC-1295 with DAC and the limits of the current evidence

Across the sources in the evidence block, the material on CJC-1295 with DAC is dominated by classification, market analysis and study design rather than reported efficacy endpoints. The compound is named as a GHRH analogue within the GH-IGF-1 axis literature [1], it appears in the context of gray-market purity and abundance testing [2], it sits within gerontological peptide reviews [3], and it is placed on the unapproved side of the approved-versus-unapproved divide in sports medicine reviews [4][5]. The one study record specific to it is a Phase 2 design in an HIV-associated visceral obesity population [6]. Where the evidence block does not report a result, no result is asserted here. Readers should treat any claim about this compound that is not traceable to a study record as unsupported by the material summarised on this page.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here is a recommendation for use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp